Research workbench
Structure of L1196M mutant anaplastic lymphoma kinase in complex with crizotinib
Analyse Structure of L1196M mutant anaplastic lymphoma kinase in complex with crizotinib in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.
- PDB
- 2YFX
- Type
- protein
- Length
- 292 residues
- Chains
- 1
- Method
- x-ray diffraction
- Collection
- MolNFT v1 / PDB
- Contract
- 0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
- Owner
- 0x3396CDB397284571d12822B4ae1189a8E22AAAAA
- Molecule
- Tyrosine-protein kinase receptor
- EC
- 2.7.10.1
- UniProt
- B6EXY4
- Ligands
- VGH
- Pockets
- 1 · best druggability 0.62
Structure
x-ray diffraction · 1 distinct chain · 43% helix, 14% strand (DSSP).
| Chain | Molecule | Type | Residues | Secondary structure | UniProt |
|---|---|---|---|---|---|
| A | Tyrosine-protein kinase receptor (EC 2.7.10.1) | protein | 292 | 43% helix, 14% strand | B6EXY4 |
Ligands and binding sites
- VGH · 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-amine · ligand · chains A
Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.
Pockets
1 pocket found on a 1 Å grid, 1 with a druggability of 0.5 or more.
| Volume (ų) | Druggability | Buriedness | Lining residues | Inside | |
|---|---|---|---|---|---|
| 1 | 373 | 0.62 | 0.77 | 43 | VGH |
Compared structures
- 2YFX · Structure of L1196M Mutant Anaplastic Lymphoma Kinase in Complex with Crizotinib · the same entry in another collection · chain A against A, TM-score 1.00
Analyse
- Open in the research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides and crosslinks on the 3D structure
- Every structure of UniProt B6EXY4
- Elsewhere: RCSB PDB 2YFX · PDBe 2YFX · UniProt B6EXY4
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.